Echosens North America press releases
Echosens urges increased vigilance around liver health during May 2020 Hepatitis Awareness Month and calls attention to the millions of Americans from all walks of life who are living with the most common causes of viral hepatitis: hepatitis B virus (HBV) and hepatitis C virus (HCV).
March 31, 2020, Published in Business Wire
Echosens, proudly announces its collaboration with MetaPhy Health to support turn-key, comprehensive chronic disease management services to gastroenterology practices for their patients with fatty liver disease. FibroScan, a non-invasive, rapid and painless examination to accurately detect, assess and monitor liver fat and stiffness, is a cornerstone of the Echosens patient-centered care model designed to improve individual health outcomes, lower payer costs by avoiding expensive, invasive interventions and enhance the financial performance of gastroenterology practices.
Chris Oubre, president, and chief operating officer of MetaPhy Health says,
“We’re very excited to join forces with Echosens to improve care coordination and develop and implement a comprehensive care plan for patients with non-alcoholic fatty liver disease (NAFLD), fibrotic non-alcoholic steatohepatitis (NASH), Type 2 diabetes, obesity and/or the underlying metabolic syndrome conditions that contribute to the progression or risk of developing advanced liver disease. Many individuals with gastrointestinal issues are also living with other chronic diseases that can be improved through early detection, monitoring, patient education and engagement.”
NAFLD affects approximately 85 million Americans, and its progressive form, NASH with fibrosis, is estimated to affect 16 million. NAFLD and NASH are becoming the leading cause of liver cancer and cirrhosis in the United States and the leading indication for a liver transplant.
Dr. Reed Hogan, M.D., GI Associates (GIA) in Flowood, Mississippi, says the practice has successfully integrated its FibroScan capabilities with the MetaPhy CCM programs.
“With the MetaPhy partnership, GIA is able to provide services to patients across the spectrum of NAFLD, leveraging FibroScan to monitor and engage patients. Effective lifestyle modification has been shown to cease and often reverse the progression of fibrotic NASH. By engaging patients in this comprehensive care program, we hope to improve patient outcomes and reduce costs, while also enhancing practice performance.”
GIA is not only experiencing fiscal benefits from its NAFLD program but also providing a valuable service to its community where viable treatment options for NAFLD have traditionally been scarce.
Jon Gingrich, CEO, Echosens North America, says the MetaPhy focus on helping practices manage liver
the disease provides an ideal opportunity to incorporate FibroScan as a way to
effectively impact overall patient outcomes.
“While finding and managing fibrotic NASH is an important component to addressing liver disease, patients with steatosis alone are at a greater risk of cardiovascular mortality and morbidity. For these patients, FibroScan has become the centerpiece of the GIA CCM program, which has been shown to reduce costs and improve outcomes in this population. In the GI setting where the volume of NAFLD/metabolic syndrome patients is overwhelming, the profitability of CCM really drives this ancillary.”
MetaPhy Health partners with gastroenterology practices to provide comprehensive chronic disease management services to their patient populations. Through this partnership, physicians can provide patients with a safe, easy, and cost-effective way to identify, measure, and manage the severity of their chronic GI-related conditions. MetaPhy’s disease management services are delivered via a telehealth platform comprised of a Virtual Care Team, and these comprehensive services are designed to encourage a healthier lifestyle for long-term results. For more information, please visit www.metaphyhealth.com.
Echosens shares a mission with the Fatty Liver Foundation to reach into every community in America to ensure asymptomatic individuals receive the screening and care they need.
Echosens proudly announces the publication of the “FibroScan-AST (FAST) Score in The Lancet Gastroenterology & Hepatology.
Echosens aligns with the Fatty Liver Foundation to accelerate screening for undiagnosed NAFLD-NASH patients.
Echosens calls for increased vigilance by healthcare providers to monitor liver health at the point of care, address obesity, diabetes and halt progression of NAFLD.
Echosens will provide a live demonstration of a FibroScan examination, in partnership with Fidelis, at the Department of Veterans Affairs’ (VA) National Veterans Small Business Engagement
FAST is a cost-effective tool to help identify individuals at risk for fibrotic NASH, an asymptomatic progressive liver disease that leads to increased liver-related mortality and morbidity.
Echosens joins the American Liver Foundation in observance of Liver Cancer Awareness Month, urging increased awareness of non-alcoholic fatty liver disease (NAFLD) and its more severe form called non-alcoholic steatohepatitis (NASH
Addressing the risk for cirrhosis, liver failure and liver cancer among America’s veterans
© 2020 echosens.